Selective O-GlcNAcase Inhibitors via Local Quality Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a challenge in developing selective inhibitors for O-GlcNAcase, as non-selective inhibitors often inhibit related enzymes, leading to complex phenotypes and making it difficult to study the cellular and organismal physiological role of O-GlcNAcase effectively.
Innovation Solution
The development of specific compounds represented by structural formulas that act as potent and selective O-GlcNAcase inhibitors, which can be used to treat various diseases associated with proteins modified by O-GlcNAcase.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective inhibitors are used to block O-GlcNAcase function, then inhibition potency is achieved, but selectivity is lost leading to concomitant inhibition of lysosomal beta-hexosaminidases and complex phenotypes
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features that target only O-GlcNAcase. The compounds contain a beta-N-acetylglucosamine mimic core structure with specific substituent patterns (aromatic groups at positions 2 and 6, specific ring configurations) that create a unique binding profile matching the O-GlcNAcase active site geometry, while excluding lysosomal beta-hexosaminidases through steric and electronic complementarity requirements.
Solution Approach 2:
The patent employs asymmetry by developing chiral inhibitors with specific stereochemistry. The compounds feature defined stereocenters (e.g., (2S,4R), (2R,4S), (2S,4S), (2R,4R) configurations) that create asymmetric binding interactions with O-GlcNAcase, enabling enantioselective inhibition. This asymmetric design ensures high affinity for O-GlcNAcase while maintaining selectivity against other glycosidases that may have different chiral recognition requirements.
2Reliability
If existing beta-N-acetylglucosaminidase inhibitors are used, then O-GlcNAcase inhibition is achieved, but lysosomal beta-hexosaminidases are also inhibited causing complex phenotypes
Solution Approach 1:
The patent applies parameter changes by systematically modifying molecular parameters of the beta-N-acetylglucosamine mimic core. Specific substitutions include aromatic groups (phenyl, naphthyl, heteroaryl) at positions 2 and 6, varying ring sizes (5-membered vs 6-membered rings), adjusting substituent positions (ortho, meta, para), and modifying linker characteristics. These parameter changes create a chemical space of compounds with optimized binding affinity for O-GlcNAcase while reducing off-target effects on lysosomal enzymes through subtle differences in molecular recognition.
Data Source
AI summary
Described herein are compounds represented by formulas (IA) or (IB)or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables R1, R3, R4, Y1, Y2, Ar, Z and n are as defined herein.